ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-Week results

AIDS

Volumn 15, Issue 1, 2001, Pages

  Murphy, Robert L ^a   Brun, Scott ^b   Hicks, Charles ^c   Eron, Joseph J ^d   Gulick, Roy ^e   King, Martin ^b   White Jr , A Clinton ^f   Benson, Constance ^g   Thompson, Melanie ^h   Kessler, Harold A ⁱ   Hammer, Scott ^j   Bertz, Richard ^b   Hsu, Ann ^b   Japour, Anthony ^b   Sun, Eugene ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h AIDS Research Consortium of Atlanta   (United States)

ⁱ RUSH MEDICAL COLLEGE   (United States)

^j Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

ABT 378; ABT 378 r; Antiretroviral naive; Phase II clinical study; Protease inhibitor

Indexed keywords

LAMIVUDINE; LOPINAVIR; RITONAVIR; STAVUDINE; VIRUS RNA;

ANTIMICROBIAL THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINASE INHIBITION; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; STAVUDINE; VIRAL LOAD;

EID: 17044457875     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101050-00002     Document Type: Article

References (27)

1. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
2. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up
3. Treatment with amprenavir alone or with zidovudine and lamivudine in adults with human immunodeficiency virus infection
4. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients
5. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
6. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
7. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers
8. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficlency virus infection and CD4 cell counts of 200 per cubic millimeter or less
9. Meta-analysis of efficacy of triple combination therapy in antiretroviral-naive HIV-1-infected adults
10. Antiretroviral treatment in 1998
11. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
12. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
13. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction
14. Single dose pharmacokinetics of ABT-378 in combination with ritonavir
15. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir
16. Multiple-dose pharmacokinetics (PK) of ABT-378/ritonavir (ABT-378/r) in HIV+ subjects
17. Human serum alternates the activity of 1996 protease inhibitors toward wild-type human immunodeficiency virus
18. An open-label, randomized comparative study of stavudine (d4T) + lamivudine (3TC) + indinavir (IDV) versus zidovudine (ZDV) + 3TC + IDV in treatment of HIV-infected patients (START I)
19. A comparison of stavudine, didanosine, and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START 1)
20. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
21. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients
22. Agenerase (amprenavir) capsules
23. A dose finding study of once-daily indinavir/ritonavir plus combivir in HIV infected patients
24. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
25. Pharmacodynamics (PD) of indinavir (IDV) in protease-naive HIV-infected patients receiving ZDV and 3TC
26. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial